INMB Q1 2022 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$163,000+3975.0% YoY

Gross Profit

$163,000100.0% margin

Operating Income

-$6M-3974.2% margin

Net Income

-$7M-4235.0% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+0.0%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$94M

Total Liabilities

$19M

Stockholders' Equity

$76M

Cash & Equivalents

$67M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$163,000	$4,000	+3975.0%
Gross Profit	$163,000	$4,000	+3975.0%
Operating Income	-$6M	-$5M	-42.4%
Net Income	-$7M	-$5M	-51.5%